TLDR
- Corexa Pharmacy topped $600,000 in July revenue with a $7 million run rate.
- DataMeds expands GLP-1 access through oral and injectable treatment options.
- Health Lives Here is set for a September public rollout starting in North Carolina.
- Corexa adds supplements and non-GLP-1 medicines to broaden pharmacy sales reach.
- Former NFL players will support marketing for app downloads and prescription growth.
DataMeds AI closed at $1.39 on August 11, down 13.13% during regular trading. Shares later rose 1.44% to $1.41 after hours as the company outlined Corexa Pharmacy’s latest operating milestones. The update places the pharmacy business at the center of DataMeds’ growth plans for the second half of 2026.
Corexa Pharmacy Revenue Supports H2 Growth Plan
Corexa Pharmacy generated more than $600,000 in July revenue, giving the business an annualized run rate above $7 million. That level gives DataMeds a stronger operating base as it expands pharmacy services, product access, and digital distribution channels. The company expects new product categories and wider telemedicine access to support additional revenue during the second half of 2026.
Corexa Pharmacy also completed its rebrand from Wellgistics Pharmacy, creating a clearer identity within DataMeds’ expanding healthcare operations. Management paired the rebrand with infrastructure upgrades and new proprietary sales channels designed to broaden customer access nationwide. These changes give the pharmacy a larger role across DataMeds’ pharmacy, telemedicine, technology, and consumer health services nationwide.
The company also expanded beyond GLP-1 therapies by adding medicines for other conditions and related healthcare needs. That broader portfolio allows Corexa Pharmacy to serve patients who require additional prescriptions alongside weight-management treatments and ongoing care. It also expands the pharmacy’s addressable market and reduces dependence on one treatment category for future sales growth.
GLP-1 Access Expands Through Corexa Pharmacy
Corexa Pharmacy registered with TrumpRx and can now provide access to several oral GLP-1 weight-management medicines for eligible patients. The pharmacy also offers injectable GLP-1 therapies, giving patients access to multiple treatment formats through one pharmacy channel. Some oral treatments may cost patients as little as $149 out of pocket under the available access program.
The pharmacy also added Forzet, a medical food designed for dietary management during GLP-1-based weight-loss treatment and related care. Corexa Pharmacy plans to sell Forzet alongside prescribed therapies, linking medication access with complementary nutritional support for patients. This approach adds another revenue stream while widening the pharmacy’s product offering for weight-management customers using GLP-1 therapies.
Corexa Pharmacy now carries Galectovid and Tollovid, along with other dietary supplements and nutraceutical products for broader consumer demand. These additions allow customers to combine prescriptions and selected health products through the same pharmacy platform and online store. The broader catalog also supports DataMeds’ strategy to increase purchasing activity across its expanding healthcare services and pharmacy network.
Health Lives Here App Extends Pharmacy Reach
DataMeds integrated the Corexa online store into its Health Lives Here mobile application as another direct sales and service channel. The app supports telemedicine visits, prescription access, refills, product purchases, and health-data monitoring during ongoing treatment. DataMeds introduced the platform at the 2026 Pro Football Hall of Fame Game for former NFL players.
The company plans a public launch in September 2026, beginning with a staged rollout in North Carolina. States should follow later in 2026 as DataMeds expands access and completes local operating requirements across targeted markets nationwide. The wider rollout could connect more patients directly with Corexa Pharmacy through a single digital healthcare channel.
DataMeds also plans a marketing campaign led by former NFL players and supported alongside NFL Alumni Health. The campaign will target app downloads, telemedicine visits, GLP-1 prescriptions, and sales of related products through Corexa Pharmacy. The pharmacy expansion and app rollout form DataMeds’ main commercial growth push for the remainder of 2026.
The post DataMeds AI, Inc. (MEDS) Stock: Corexa Pharmacy Eyes Stronger H2 2026 Growth appeared first on Blockonomi.
